FR940125-2-00015 FR940125-2-00005 The proposed Consent Order also prohibits the proposed respondents from representing, directly or by implication, that Face Lift, or any substantially similar product or service, (1) can or will permanently remove facial wrinkles; or (2) is as effective as, or more effective than, the prescription drug Tretinoin (currently marketed as Retin-A) in the removal of facial wrinkles. In addition, the proposed Consent Order prohibits the proposed respondents from representing, directly or by implication, the efficacy of any other product or service in the treatment of facial wrinkles, or that such other product or service is as effective as, or more effective than, any other product or service in the treatment of facial wrinkles, unless such representation is true and, at the time of making such representation, respondents possess and rely upon competent and reliable scientific evidence that substantiates the representation. The proposed Consent Order also prohibits the proposed respondents from representing, directly or by implication, that Celltrex, or any substantially similar product or service, can or will promote the healing of third degree burns. In addition, the proposed Consent Order prohibits the proposed respondents from representing, directly or by implication, that any other product or service will promote the healing of, or is otherwise an effective treatment for burns, unless such representation is true and, at the time of making such representation, respondents possess and rely upon competent and reliable scientific evidence that substantiates the representation. The proposed Consent Order also prohibits the proposed respondents from making any representation, directly or by implication, (1) regarding the performance, benefits, efficacy or safety of any food, drug, or device, unless at the time of making such representation respondents possess and rely upon competent and reliable scientific evidence that substantiates the representation; and (2) regarding the performance, benefits, efficacy or safety of any other product or service, unless at the time of making such representation respondents possess and rely upon competent and reliable evidence, which when appropriate must be competent and reliable scientific evidence, that substantiates the representation. The proposed Consent Order also prohibits the proposed respondents from, (1) misrepresenting, in any manner, the past, present, or future profits, earnings, income, or sales from participation of any person in any distribution, sales, or marketing plan; and (2) representing, in any manner, directly or by implication, by use of hypothetical examples or otherwise, that distributors earn or achieve from participation in any distribution, sales, or marketing plan any stated amount of profits, earnings, income, or sales in excess of the average profits, earnings, income, or sales of all distributors, unless in conjunction therewith such average profits, earnings, income, or sales are clearly and conspicuously disclosed, and the percent of all distributors who actually achieved such stated profits, earnings, income, or sales in such time period is clearly and conspicuously disclosed. The proposed Consent Order also contains provisions requiring proposed respondent NU Skin International, Inc., to discontinue dealing with any person who makes any of the representations for Nutriol, Face Lift, Celltrex, or any substantially similar products or services, that are expressly prohibited by the Order. Nu Skin must also discontinue dealing with any person who Nu Skin knows is engaged in any other acts or practices prohibited by the Order, unless the person immediately ceases engaging in such acts or practices. The proposed Consent Order also contains provisions requiring distribution of the Order or a summary of the Order to all current and future officers, agents, representatives, employees, and distributors of the proposed respondents; record retention demonstrating compliance with the Order; and notification to the Commission of any changes in the structure of the proposed corporate respondents or the employment of the individual respondents. Finally, the proposed Consent Order requires proposed respondent Nu Skin International, Inc., to pay the Federal Trade Commission $1,000,000, and proposed respondents CJM, Inc., CST Management, Inc., CK&C, Inc., Clara McDermott, Craig Tillotson, and Craig Bryson to pay the Federal Trade Commission $225,000. The funds paid by the proposed respondents shall, in the discretion of the Federal Trade Commission, be used to provide direct redress to consumers. If the Federal Trade Commission determines that consumer redress is impracticable or otherwise unwarranted, any funds not so used shall be paid to the United States Treasury. The purpose of this analysis is to facilitate public comment of the proposed Order. It is not intended to constitute an official interpretation of the agreement and proposed Order or to modify in any way their terms. Donald S. Clark, Secretary. [FR Doc. 94&hyph;1561 Filed 1&hyph;24&hyph;94; 8:45 am] BILLING CODE 6750&hyph;01&hyph;M
